Kimberly L. Blackwell, MD, Duke University School of Medicine
Kimberly L. Blackwell, MD: The recent approval of ribociclib really confirms—in my mind, the data confirm—that a CDK inhibitor should be used in the first-line setting. And now, I’m really looking at things that could really help my patients’ lives be a little easier, including things like having the letrozole packaged with the ribociclib. That seems like a small deal, but when you have a drug that you have to give for 3 weeks and then 1 week off and another drug that you have to give every day, having a bubble package where patients know, “Oh, it’s 2, I’m going to take 1 of the letrozole and several of the ribociclib,” I think that’s really going to make a difference.
And so, I’m excited to see how each of the companies that are manufacturing the CDK inhibitors will help us make our patients’ lives easier with patient education and information, even just in the way that they’re distributing the drugs. Because I think they’re here to stay, and I think the CDK inhibitors really are the standard of care for first-line treatment of recurrent or metastatic hormone-sensitive breast cancer.